Cannabis-Derived Pharmaceuticals.
- Published in:
- Journal of Commercial Biotechnology, 2015, v. 21, n. 3, p. 16, doi. 10.5912/jcb709
- By:
- Publication type:
- Article
Works matching IS 14628732 AND DT 2015 AND VI 21 AND IP 3
Results: 9
1
2
Off-Label on the Table.
- Published in:
- 2015
- By:
- Publication type:
- Opinion
3
The Globetrotting Regulator.
- Published in:
- 2015
- By:
- Publication type:
- Opinion
4
EU Legal & Regulatory Update - June 2014.
- Published in:
- Journal of Commercial Biotechnology, 2015, v. 21, n. 3, p. 45, doi. 10.5912/jcb710
- By:
- Publication type:
- Article
5
BioTime's bid to end age-related disease: A look at CEO Michael West's Vision.
- Published in:
- Journal of Commercial Biotechnology, 2015, v. 21, n. 3, p. 42, doi. 10.5912/jcb706
- By:
- Publication type:
- Article
6
Innovation Landscape, Deal-making Strategies and Success Stories.
- Published in:
- 2015
- By:
- Publication type:
- Proceeding
7
Venture Capitalists as Gatekeepers for Biotechnological Innovation.
- Published in:
- Journal of Commercial Biotechnology, 2015, v. 21, n. 3, p. 32, doi. 10.5912/jcb704
- By:
- Publication type:
- Article
8
Combating a Global Pandemic of Weak, Adulterated, and Fake Drugs.
- Published in:
- Journal of Commercial Biotechnology, 2015, v. 21, n. 3, p. 3, doi. 10.5912/jcb712
- By:
- Publication type:
- Article
9
A 'Genetically Engineered' Label: Way More Expensive Than You Think.
- Published in:
- Journal of Commercial Biotechnology, 2015, v. 21, n. 3, p. 13, doi. 10.5912/jcb713
- By:
- Publication type:
- Article